Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AXSM Axsome Therapeutics	$121.28 -0.4%	$107.80	$75.56 ▼ $139.13	$6.05B	0.51	764,976 shs	351,676 shs
CDTX Cidara Therapeutics	$65.39 +0.2%	$57.18	$10.14 ▼ $69.36	$1.66B	1.18	379,230 shs	188,319 shs
LEGN Legend Biotech	$34.73 +1.0%	$37.77	$27.34 ▼ $59.62	$6.38B	0.26	1.45 million shs	881,286 shs
RNA Avidity Biosciences	$46.58 -4.1%	$37.05	$21.51 ▼ $56.00	$5.99B	0.95	1.85 million shs	1.44 million shs

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AXSM Axsome Therapeutics	-0.09%	+3.94%	+21.25%	+16.04%	+37.68%
CDTX Cidara Therapeutics	-0.24%	-3.35%	+5.33%	+195.69%	+402.16%
LEGN Legend Biotech	-1.01%	-3.26%	-15.70%	+19.55%	-39.34%
RNA Avidity Biosciences	+1.59%	+8.78%	+35.13%	+56.81%	+11.35%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AXSM Axsome Therapeutics	4.8357 of 5 stars	4.5	1.0	4.5	4.0	4.2	0.6
CDTX Cidara Therapeutics	3.6206 of 5 stars	2.6	3.0	4.6	2.7	1.7	0.0
LEGN Legend Biotech	3.8839 of 5 stars	4.5	4.0	0.0	3.4	1.7	0.6
RNA Avidity Biosciences	3.1382 of 5 stars	4.5	2.0	0.0	4.0	0.8	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AXSM Axsome Therapeutics	3.07	Buy	$178.00	46.39% Upside
CDTX Cidara Therapeutics	3.11	Buy	$64.14	-2.13% Downside
LEGN Legend Biotech	2.91	Moderate Buy	$74.22	114.34% Upside
RNA Avidity Biosciences	3.06	Buy	$67.00	44.06% Upside

Current Analyst Ratings Breakdown

Latest CDTX, LEGN, RNA, and AXSM Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/27/2025	LEGN Legend Biotech	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight	$66.00
8/25/2025	LEGN Legend Biotech	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$77.00 ➝ $78.00
8/12/2025	LEGN Legend Biotech	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$75.00 ➝ $77.00
8/12/2025	LEGN Legend Biotech	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$81.00 ➝ $83.00
8/8/2025	CDTX Cidara Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
8/8/2025	CDTX Cidara Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Market Outperform ➝ Market Outperform	$59.00 ➝ $66.00
8/8/2025	CDTX Cidara Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$53.00 ➝ $74.00
8/8/2025	CDTX Cidara Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$54.00 ➝ $74.00
8/8/2025	RNA Avidity Biosciences	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$70.00 ➝ $75.00
8/8/2025	RNA Avidity Biosciences	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$59.00 ➝ $62.00
8/8/2025	RNA Avidity Biosciences	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$75.00

(Data available from 8/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AXSM Axsome Therapeutics	$385.69M	15.73	N/A	N/A	$1.46 per share	83.28
CDTX Cidara Therapeutics	$1.27M	1,308.68	N/A	N/A	$19.76 per share	3.32
LEGN Legend Biotech	$796.84M	7.99	N/A	N/A	$5.64 per share	6.14
RNA Avidity Biosciences	$10.90M	548.95	N/A	N/A	$9.27 per share	5.02

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AXSM Axsome Therapeutics	-$287.22M	-$5.07	N/A	43.12	N/A	-49.88%	-283.22%	-33.06%	11/11/2025 (Estimated)
CDTX Cidara Therapeutics	-$169.83M	-$11.13	N/A	N/A	N/A	N/A	-50.81%	-42.46%	11/6/2025 (Estimated)
LEGN Legend Biotech	-$177.03M	-$0.88	N/A	N/A	N/A	-40.83%	-32.00%	-20.07%	11/11/2025 (Estimated)
RNA Avidity Biosciences	-$322.30M	-$3.56	N/A	N/A	N/A	-4,247.77%	-33.45%	-30.22%	11/6/2025 (Estimated)

Latest CDTX, LEGN, RNA, and AXSM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2025	Q2 2025	LEGN Legend Biotech	-$0.22	-$0.34	-$0.12	-$0.34	$237.49 million	$255.06 million
8/7/2025	Q2 2025	CDTX Cidara Therapeutics	-$1.87	-$1.65	+$0.22	-$1.65	N/A	N/A
8/4/2025	Q2 2025	AXSM Axsome Therapeutics	-$1.00	-$0.92	+$0.08	-$0.97	$140.02 million	$150.04 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AXSM Axsome Therapeutics	N/A	N/A	N/A	N/A	N/A
CDTX Cidara Therapeutics	N/A	N/A	N/A	N/A	N/A
LEGN Legend Biotech	N/A	N/A	N/A	N/A	N/A
RNA Avidity Biosciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AXSM Axsome Therapeutics	1.66	1.57	1.51
CDTX Cidara Therapeutics	N/A	16.45	16.45
LEGN Legend Biotech	0.30	4.71	4.57
RNA Avidity Biosciences	N/A	9.26	9.26

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AXSM Axsome Therapeutics	81.49%
CDTX Cidara Therapeutics	35.82%
LEGN Legend Biotech	70.89%
RNA Avidity Biosciences	N/A

Insider Ownership

Company	Insider Ownership
AXSM Axsome Therapeutics	22.30%
CDTX Cidara Therapeutics	3.89%
LEGN Legend Biotech	0.02%
RNA Avidity Biosciences	3.83%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AXSM Axsome Therapeutics	380	49.90 million	38.77 million	Optionable
CDTX Cidara Therapeutics	90	25.36 million	24.37 million	No Data
LEGN Legend Biotech	2,609	183.76 million	183.73 million	Optionable
RNA Avidity Biosciences	190	128.65 million	123.73 million	Optionable

CDTX, LEGN, RNA, and AXSM Headlines

Recent News About These Companies

Invesco Ltd. Purchases 193,376 Shares of Avidity Biosciences, Inc. $RNA

August 28 at 3:26 AM | marketbeat.com

Avidity Biosciences to Participate in Upcoming Investor Conferences

August 27 at 9:00 AM | prnewswire.com

BI Asset Management Fondsmaeglerselskab A S Sells 52,463 Shares of Avidity Biosciences, Inc. $RNA

August 27 at 4:26 AM | marketbeat.com

Price T Rowe Associates Inc. MD Purchases 295,275 Shares of Avidity Biosciences, Inc. $RNA

August 26 at 4:58 AM | marketbeat.com

771,158 Shares in Avidity Biosciences, Inc. $RNA Acquired by T. Rowe Price Investment Management Inc.

August 26 at 4:49 AM | marketbeat.com

RNA Stock Moves More Than 30% in a Week: What's Driving This Rally?

August 25, 2025 | zacks.com

Nuveen LLC Invests $12.73 Million in Avidity Biosciences, Inc. $RNA

August 24, 2025 | marketbeat.com

Avidity Biosciences (NASDAQ:RNA) Insider Sells $102,451.20 in Stock

August 23, 2025 | insidertrades.com

Candriam S.C.A. Increases Stock Position in Avidity Biosciences, Inc. $RNA

August 23, 2025 | marketbeat.com

Wellington Management Group LLP Has $285.89 Million Stock Holdings in Avidity Biosciences, Inc. $RNA

August 22, 2025 | marketbeat.com

Aberdeen Group plc Increases Holdings in Avidity Biosciences, Inc. $RNA

August 22, 2025 | marketbeat.com

Avidity Biosciences, Inc. $RNA Shares Sold by Swiss National Bank

August 22, 2025 | marketbeat.com

Avidity Biosciences Sees Unusually High Options Volume (NASDAQ:RNA)

August 21, 2025 | marketbeat.com

Avidity Biosciences (NASDAQ:RNA) Trading Down 4.2% on Insider Selling

August 20, 2025 | marketbeat.com

Avidity Biosciences, Inc. (NASDAQ:RNA) Receives $67.00 Consensus PT from Analysts

August 20, 2025 | americanbankingnews.com

Avidity Biosciences (NASDAQ:RNA) Stock Price Down 4.2% on Insider Selling

August 20, 2025 | americanbankingnews.com

Avidity Biosciences, Inc. $RNA Holdings Cut by Vanguard Group Inc.

August 19, 2025 | marketbeat.com

Avidity Biosciences, Inc. (NASDAQ:RNA) Shares Purchased by Citigroup Inc.

August 18, 2025 | marketbeat.com

Avidity Biosciences, Inc. (NASDAQ:RNA) Shares Sold by Deutsche Bank AG

August 18, 2025 | marketbeat.com

Avidity Biosciences, Inc. (NASDAQ:RNA) Insider Sells $465,600.00 in Stock

August 17, 2025 | marketbeat.com

Teresa Mccarthy Sells 10,000 Shares of Avidity Biosciences, Inc. (NASDAQ:RNA) Stock

August 16, 2025 | insidertrades.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

CDTX, LEGN, RNA, and AXSM Company Descriptions

Axsome Therapeutics NASDAQ:AXSM

$121.28 -0.47 (-0.39%)

Closing price 04:00 PM Eastern

Extended Trading

$121.25 -0.03 (-0.02%)

As of 04:39 PM Eastern

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.

Cidara Therapeutics NASDAQ:CDTX

$65.39 +0.16 (+0.25%)

Closing price 04:00 PM Eastern

Extended Trading

$65.40 +0.01 (+0.02%)

As of 04:38 PM Eastern

Cidara Therapeutics, Inc., a biotechnology company, focuses on developing targeted therapies for patients facing cancers and other serious diseases. The company's product includes rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also develops its Cloudbreak platform that enables development of novel drug-Fc conjugates, that includes CD388, a potent antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which is in Phase 1 and Phase 2a clinical trials. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. The company was incorporated in 2012 and is based in San Diego, California.

Legend Biotech NASDAQ:LEGN

$34.73 +0.36 (+1.05%)

Closing price 04:00 PM Eastern

Extended Trading

$34.50 -0.23 (-0.67%)

As of 05:25 PM Eastern

Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. The company was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.

Avidity Biosciences NASDAQ:RNA

$46.58 -2.00 (-4.12%)

Closing price 04:00 PM Eastern

Extended Trading

$46.50 -0.08 (-0.17%)

As of 05:38 PM Eastern

Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat diseases previously untreatable with RNA therapeutics. The company's lead product candidate AOC 1001 for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease that is in phase 1/2 clinical trial. Its other products in pipeline include AOC 1044 for the treatment of duchenne muscular dystrophy, which is under phase 1/2 clinical development trial; and AOC 1020 to treat facioscapulohumeral muscular dystrophy that is in phase 1/2 clinical trial. The company is developing products for rare skeletal muscle and rare cardiac diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time